• Category: Pharma
  • Investment Status: IPO
  • Medical Field: Oncology
  • Patent Status: National phase. Granted in several regions
  • Development Status: clinical trials
  • Medical Center: Rabin Medical Center
  • Inventors: Dr. Moshe Yeshurun

Kalytera Therapeutics is a clinical-stage pharmaceutical company developing cannabinoid therapeutics. Through its proven leadership, drug development expertise, and growing intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on Graft versus Host Disease (“GvHD”).